JPM 2023: Boston Scientific Sees Transformational Potential In PFA, BD Sticks To '2025' Investment Strategy

Also: Insulet and Tandem Address Unmet Need In Insulin Pumps

 
• By Reed Miller and Marion Webb

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations on the third day of the meeting.

J.P. Morgan Daily Notebook: Day 3
• Source: Shutterstock

Boston Scientific expects the Farapulse pulsed field ablation (PFA) technology to provide a much-needed competitive edge in electrophysiology, a market where the company lags far behind its most important competitors.

Electrophysiologists and ablation catheter developers expect pulsed field ablation (PFA) to become the dominant cardiac ablation technology in the next...

More from Strategy

More from Business